

Erika Hamilton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3310627/publications.pdf>

Version: 2024-02-01

12
papers

580
citations

1307594

7
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

580
citing authors

#	ARTICLE	IF	CITATIONS
1	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2 ⁺ , Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	1.6	478
2	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2.	2.4	23
3	Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2568-2577.	1.6	18
4	Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. <i>Nature Cancer</i> , 2022, 3, 927-931.	13.2	12
5	A Big World Made Small: Using Social Media to Optimize Patient Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e212-e218.	3.8	11
6	Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100456.	3.0	11
7	Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. <i>JCO Precision Oncology</i> , 2021, 5, 1297-1311.	3.0	9
8	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731.	3.7	6
9	A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2 ⁺ early breast cancer in the United States. <i>BMC Cancer</i> , 2022, 22, 502.	2.6	4
10	Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC). <i>Cancer Research</i> , 2022, 82, P5-16-02-P5-16-02.	0.9	3
11	nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR ⁺ , HER2 ⁻ metastatic breast 2.5 cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 55-64.		3
12	Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 805-814.	2.4	2